The Lancet6d
A step towards more physiological glucocorticoid dosing in congenital adrenal hyperplasia
On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...
Finanznachrichten15d
Harbour BioMed: HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies
HAT001/HBM9013 is designed to neutralize CRH for various disorders, including congenital adrenal hyperplasia (CAH ... collaboration represents a pivotal step for HBMAT in our mission to deliver ...
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director Oxford, United Kingdom - 26 February 2025 - OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medi ...
clinicaltrialsarena16d
Sterotherapeutics begins Phase II trial for ST-002 targeting Cushing’s Syndrome
“This trial represents a significant step forward in our mission to develop transformative therapies for unmet medical needs. Collaboration with our expert investigators is essential to ensuring the ...
Science Daily21d
Hidden genetic causes of congenital heart disease identified
Scientists have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect. Scientists at the Icahn School of Medicine at Mount Sinai and ...
Medical Xpress29d
Simple congenital heart diseases tied to higher epilepsy risk
Among simple congenital heart diseases (CHD), patent foramen ... and PDA (risk ratios [95 percent confidence intervals], 3.28 [2.00 to 5.43], 1.47 [0.79 to 2.68], and 1.46 [0.70 to 2.82 ...